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Anatomy	  of	  mediastinum	  
The	   mediastinum	   is	   a	   thoracic	   space	   between	   the	   two	   pleural	  
cavities;	   it	   extends	   from	   the	   superior	   thoracic	   inlet	   to	   the	   superior	  
surface	  of	  diaphragm.	  
The	   mediastinum	   is	   anatomically	   subdivided	   in	   different	  
compartments,	   defined	   as	   anterior,	   middle	   and	   posterior	  
compartment.	  
The	   anterior	   compartment	   normally	   contains	   the	   thymus	   gland,	  
internal	  mammary	  vessels,	  lymph	  nodes,	  connective	  tissue	  and	  fat.	  At	  
times,	  parathyroid	  glands	  and	  ectopic	  thyroid	  tissue	  may	  be	  foudend	  
in	  the	  mediastinum.	  
The	  middle	   compartment,	   called	   visceral,	   contains	   the	   pericardium,	  
heart	   and	  great	   vessels.	   The	   trachea,	  proximal	  portions	  of	   the	   right	  
and	   left	   mainstem	   bronchi,	   and	   esophagus	   are	   the	   major	   visceral	  
structures.	   Lymphatic	   tissue,	   the	   vagus	   and	   phrenic	   nerves,	   the	  
supra-­‐aortic	   and	   para-­‐aortic	   bodies,	   multiple	   nerve	   plexuses	   and	  
fibers,	   the	   thoracic	  duct,	   the	  proximal	  portion	  of	   the	  azygos	  venous	  




The	   posterior	   compartment,	   contains	   the	   proximal	   portions	   of	   	   the	  
intercostal	  arteries	  and	  veins,	  proximal	  portion	  of	  the	  anterior	  ramus	  
and	   the	   rami	   communincates	   of	   the	   intercostal	   	   nerves,	   thoracic	  
spinal	   ganglions,	   sympathetic	   trunk	   and	   connective	   and	   lymphatic	  
tissues,	  as	  well	  as	  the	  distal	  azygos	  vein.	  
	  
Mediastinal	  lymph	  nodes	  
The	  mediastium	  is	  rich	  in	  lymphatics	  and	  lymph	  node	  aggregates	  that	  
drain	   the	   various	   organs	   within	   the	  mediastinum,	   the	   structures	   in	  
the	   neck	   and	   portions	   of	   those	   below	   the	   diaphragm.	   These	   lymph	  
nodes	   may	   be	   the	   site	   of	   localized	   inflammatory	   disease,	   primary	  
lymphatic	  tumors	  or	  metastatic	  disease	  from	  other	  primary	  sites.	  	  
The	   status	   of	   regional	   lymph	   nodes	   is	   a	   major	   factor	   for	   staging,	  
assigning	   treatment,	   and	   evaluating	   treatment	   efficacy	   in	   patients	  
with	  lung	  cancer1.	  
	  
Lymph	  node	  classification	  
Naruke	   and	   colleagues	   first	   described	   a	   lymph	   node	   map	   of	  
mediastinum	   and	   lungs	   in	   19782.	   In	   1997	   Mountain	   and	   Dresler	  
recommended	   a	   classification	   of	   regional	   lymph	   node	   stations	   that	  
Introduction	  
 3	  
unified	   the	   Naruke	   system	   and	   the	   system	   advocated	   by	   the	  
American	   Thoracic	   Society	   and	   the	   North	   American	   Lung	   Cancer	  
Study	   Group3.	   This	   map	   was	   adopted	   by	   the	   American	   Join	  
Committee	   on	   Cancer	   (AJCC)	   and	   the	   prognostic	   factors	   TNM	  
Committee	  of	  the	  Union	  Internationale	  Contre	  le	  Cancer	  at	  the	  1996	  
annual	  meeting.	  	  	  
In	   2009,	   the	   International	   Association	   for	   the	   Study	   of	   Lung	   Cancer	  
(IASLC)	   introduced	   a	   new	   lymph	   node	   map	   of	   the	   lungs	   and	  
mediastinum	   that	   resulted	   from	   an	   international	   and	  
multidisciplinary	   consensus4.	   The	   latter	   regional	   lymph	  node	   station	  





Figure	  1	  The	  IASLC	  lymph	  node	  map4.	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Pathological	  enlargement	  of	  mediastinal	  lymph	  nodes	  
Enlargement	  mediastinal	  lymph	  nodes	  is	  a	  common	  clinical	  condition.	  
In	  general	  10	  mm	  is	  considered	  the	  upper	  limit	  of	  normal	  node	  size.	  
Lymph	   nodes	   may	   be	   enlarged	   due	   to	   a	   variety	   of	   inflammatory,	  
infectious,	  or	  malignant	  reasons.	  Hence,	  it	  is	  important	  to	  establish	  a	  
diagnosis	  and	  to	  differentiate	  between	  benign	  and	  	  malignant	  lymph	  
node	  enlargement.	  
Mediastinal	  lymph	  node	  enlargement	  can	  result	  from	  a	  wide	  range	  of	  
pathologies.	  Node	  enlargement	  may	  be	  an	  isolated	  finding,	  or	   it	  can	  
be	  associated	  with	  other	  lung	  pathology.	  Listed	  below	  are	  conditions	  
than	  can	  result	  in	  mediastinal	  lymphadenopathy:	  
-­‐ Primary	  lung	  malignancies	  
-­‐ Metastatic	  malignancies	  (other	  primary	  cancer)	  
-­‐ Sarcoidosis	  
-­‐ Interstitial	  lung	  disease	  	  
-­‐ Mediastinal	  lymphoma	  
-­‐ Kaposi’s	  sarcoma	  
-­‐ Non	  lymphomatous	  pulmonary	  lymphoid	  disorders	  (Castleman	  
disease,	  lymphomatoid	  granulomatosis)	  
-­‐ Pulmonary	  infection	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-­‐ Occupational	  lung	  disease	  (silicosis,	  pneumoconiosis)	  
-­‐ Pulmonary	  manifestation	  of	  rheumatoid	  arthritis	  
	  
Staging	  of	  mediastinal	  cancer	  involvement	  	  
In	  the	  majority	  of	  western	  countries,	  approximately	  three-­‐fourths	  of	  
patients	  with	  lung	  cancer	  at	  the	  time	  of	  diagnosis	  present	  with	  locally	  
advanced	   or	   metastatic	   disease.	   The	   remaning	   20-­‐25%	   of	   patients	  
present	  with	  clinical	  diagnosis	  of	  early	  stage	   lung	  cancer	   (Stage	   I-­‐II),	  
generally	  resulting	  from	  an	  incidental	  finding	  or	  from	  screening,	  and	  
are	   potentially	   amenable	   to	   radical	   surgical	   treatment.	   With	   the	  
exception	  of	   the	  advanced	   stage	  patients	  who	  are	  not	   candidate	   to	  
any	   active	   treatment	   because	   of	   comorbidity	   and/or	   compromised	  
performance	  status,	  accurate	  staging	  of	  lung	  cancer	  is	  a	  pre-­‐requisite	  
for	  deciding	   the	  appropriate	   treatment5.	   The	  algorithms	   that	  where	  
developed	   in	   recent	   years	   to	   help	   deciding	   the	   best	   treatment	  
modality	  for	  each	  patient	  (surgery	  or	  chemotherapy	  or	  radiotherapy	  
or	   a	   combination	   thereof)	   are	   based	   on	   the	   careful	   assessment	   of	  
lung	   cancer	  histotype	  and	  of	  mediastinal	   lymph	  nodes’	  pathological	  
status6-­‐8.	  Moreover	  the	  diagnosis	  of	  a	  number	  of	  molecular	  markers	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of	  lung	  cancer	  (EGFR,	  ALK,	  KRAS	  etc)	  has	  become	  widely	  accepted	  as	  
a	  means	  to	  guide	  the	  administration	  of	  targeted	  therapy.9,10	  
Thus,	   adequate	   tissue	   sampling	   of	   mediastinal	   lymph	   nodes	   for	  
cyto/histological	  assessment	  and	  for	  molecular	  studies	  has	  became	  of	  
paramount	  importance	  for	  rational	  planning	  of	  lung	  cancer	  therapy.	  
Several	  techniques	  are	  available	  for	  sampling	  mediastinal	  lymp	  nodes,	  
and	   their	   use	   depends	   on	   the	   local	   expertise	   available.	   These	  
techniques	  include	  imaging	  by	  chest	  CT	  scan	  and	  PET-­‐CT	  scan	  (figure	  
2);	   endoscopy,	   thus	   [conventional	   transbronchial	   needle	   aspiration	  
(TBNA),	  endoscopic	  ultrasonography	  -­‐	  esophageal	  ultrasound	  needle	  
aspiration	  (EUS)	  and	  endobronchial	  ultrasound-­‐transbronchial	  needle	  
aspiration	   (EBUS-­‐TBNA)];	   and	   surgery	   [cervical	   mediastinoscopy,	  
video-­‐assisted	   thoracoscopic	   surgery	   (VATS),	   video-­‐assisted	  
mediastinoscopic	   lymphadenectomy	   (VAMLA)	   and	   transcervical	  




Figure	   2.	   Enlarged	  mediastinal	   lymph	   node	   (R4	   station)	   visualize	   as	   hot	   spot	  
with	  PET-­‐CT	  
	  
Indication	  of	  EBUS-­‐TBNA	  
The	   most	   common	   indications	   for	   EBUS-­‐TBNA	   are:	   lymph	   node	  
staging	  of	   lung	  cancer,	   investigation	  of	  mediastinal/hilar	  masses	  and	  
mediastinal	  lymph	  node	  enlargement.11	  	  
	  
Lung	  Cancer	  Staging	  
The	   current	   recommendations	   for	   invasive	   mediastinal	   staging	   by	  
sampling	   lymph	   node	   stations	   include	   all	   cases	   of	   diagnosed	   lung	  
cancer	   without	   distant	   metastasis,	   with	   the	   exception	   of	   cases	  
classified	   as	   Stage	   Ia	   (clinical/radiological	   staging)	   with	   negative	  
lymph	  nodes	  involment	  at	  PET/CT.	  Various	  methods	  have	  been	  used	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for	   lung	  cancer	  staging.	  Both	  CT	  and	  PET/CT	  are	  widely	  used	  for	  this	  
purpose.	   A	   prospective	   study	   involving	   102	   patients	   compared	   the	  
accuracy	  of	   CT,	   PET/CT,	   and	   EBUS-­‐TBNA	   for	   the	  detection	  of	   lymph	  
node	   metastasis	   from	   lung	   cancer.	   With	   the	   exception	   of	   patients	  
with	  extensive	  N2	  disease	  (bulky	  disease	  or	   involvement	  of	  multiple	  
ipsilateral	   lymph	  node	  stations)	  and	  N3	  disease	  diagnosed	  by	  EBUS-­‐
TBNA,	   the	   other	   patients	   underwent	   lobectomy	   with	   lymph	   node	  
dissection,	   making	   it	   possible	   to	   confirm	   the	   EBUS-­‐TBNA	  
cytohistological	   findings.	  The	  diagnostic	  accuracy	  of	  CT,	  PET/CT,	  and	  
EBUS-­‐TBNA	   was	   60.6%,	   72.5%,	   and	   98.0%,	   respectively,	   the	  
differences	  between	  the	  groups	  being	  significant	  (p	  <	  0.0001).12	  	  
A	   recent	   prospective	   study	   comparing	   EBUS-­‐TBNA	   and	  
mediastinoscopy	   demonstrated	   that	   the	   results	   of	   both	   methods	  
were	  similar	  in	  terms	  of	  mediastinal	  staging	  in	  91%	  of	  the	  evaluated	  
patients.	   The	   sensitivity,	   NPV,	   and	   diagnostic	   accuracy	   were	   81%,	  
91%,	   and	   93%,	   respectively,	   for	   EBUS-­‐TBNA,	   compared	   with	   79%,	  
90%,	   and	   93%,	   respectively,	   for	   mediastinoscopy.	   There	   were	   no	  





Lung	  cancer	  restaging	  after	  neoadjuvant	  chemotherapy	  	  
For	  lung	  cancer	  restaging	  after	  neoadjuvant	  therapy,	  it	  is	  necessary	  to	  
identify	   the	   patients	   who	   demonstrate	   reduction	   in	   staging	   and	  
therefore	  potentially	  benefit	  from	  surgical	  treatment.	  	  
A	  prospective	  study	  included	  61	  patients	  with	  stage	  IIIa	  and	  IIIb	  lung	  
cancer	   as	   determined	   by	   EBUS-­‐TBNA	   after	   neoadjuvant	  
chemotherapy.	   This	   patients	   presented	  with	   stable	   lymph	   nodes	   or	  
with	  partial	  response	  after	  chemotherapy	  as	  demonstrated	  by	  chest	  
CT	   scans,	   and	   there	   were	   fit	   for	   surgery.	   All	   of	   them	   underwent	  
restaging	   by	   EBUS-­‐TBNA.	   The	   patients	   with	   cancer-­‐negative	   EBUS-­‐
TBNA	   results	   underwent	   transcervical	   extended	   mediastinal	  
lymphadenectomy	   for	   histological	   confirmation.	   Lymph	   node	  
metastasis	  was	  detected	  by	  EBUS-­‐TBNA	  in	  18	  (30%)	  of	  the	  61	  patients	  
and	   in	  22	   (26%)	  of	   the	  85	  aspirated	  nodes.	  Metastatic	   lymph	  nodes	  
were	   identified	   in	   9	   (15%)	   of	   the	   43	   patients	   who	   underwent	  
transcervical	   extended	  mediastinal	   lymphadenectomy	   in	   7	   patients,	  
at	  lymph	  node	  stations	  accessible	  by	  EBUS-­‐TBNA	  and,	  in	  2	  patients,	  at	  
a	   station	   not	   accessible	   by	   EBUS-­‐TBNA.	   The	   sensitivity,	   specificity,	  
accuracy,	  PPV,	  and	  NPV	  of	  EBUS-­‐TBNA	   for	  detection	  of	   lymph	  node	  
metastasis	  in	  restaging	  were	  67%,	  86%,	  80%,	  91%	  e	  78%,	  respectively.	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The	   authors	   concluded	   that	   EBUS-­‐TBNA	   is	   an	   effective	   and	   safe	  
method	  for	  mediastinal	  restaging	  of	  patients	  with	  non	  small	  cell	  lung	  
cancer.14	  	  	  
	  
Mediastinal	  tumors	  
Many	   studies	   have	   demonstrated	   good	   diagnostic	   yield	   of	   EBUS-­‐
TBNA	  in	  mediastinal	  or	  peribronchial	   lesions.	  Yasufuku	  et	  al.	  studied	  
140	  patients	  with	  mediastinal	   tumors	   in	   the	  absence	  of	   lung	  cancer	  
or	   extrapulmonary	   cancer.	   The	   EBUS-­‐TBNA	  was	   diagnostic	   in	   93.6%	  
of	  all	  disorders.15	  
	  
Other	  causes	  of	  mediastinal	  enlargement	  
The	   EBUS-­‐TBNA	   procedure	   has	   been	   used	   in	   the	   investigation	   of	  
mediastinal	   and	   hilar	   lymph	   node	   enlargement	   in	   benign	   and	  
malignant	  non-­‐pulmonary	  disease	  such	  as	  lymphoma,	  sarcoidosis	  and	  
mediastinal	  lymp	  node	  tubercolosis.	  
	  
EBUS-­‐TBNA	  technique	  
Endobronchial	   ultrasound	   guided	   transbronchial	   needle	   aspiration	  
(EBUS-­‐TBNA)	  adds	  another	  minimally	   invasive	   tool	   for	   the	  diagnosis	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and	   staging	   of	   intrathoracic	   malignancies.	   EBUS-­‐TBNA	   may	   reach	  
multiple	  lymph	  node	  stations	  including	  paratracheal	  levels	  (station	  2	  
and	  4),	  subcarinal	  (station	  7)	  and	  even	  hilar	  nodes	  (station	  10	  and	  11).	  	  
Bronchoscopy	  is	  performed	  with	  a	  flexible	  videobronchoscope	  with	  a	  
7.5-­‐MHz	  linear	  ultrasound	  transducer	  probe	  (Figure	  3).	  	  
	  
Figure	  3	  EBUS	  videobronchoscope	  with	  ballon	  tip.	  
	  
All	   accessible	   lymph	   node	   stations	   are	   examined	   and	   the	   biopsy	   is	  
carried	   out,	   based	  on	   imaging	   studies,	   starting	  with	   the	   nodal	   level	  
that	  would	  yield	  the	  lowest-­‐stage	  disease,	  to	  avoid	  contamination.	  A	  
22	   or	   21-­‐gauge	   needle	   is	   placed	   throught	   the	   operative	   channel	   to	  
biopsy	  the	  targeted	  node,	  under	  realtime	  ultrasonic	  guidance	  (Figure	  
4	   and	   5).	   Doppler	   examination	   can	   be	   used	   to	   prevent	   unintended	  




                    Figure	  4	  View	  of	  mediastinal	  lymph	  node	  in	  EBUS	  
	  
 






Limitations,	  contraindications	  and	  complications	  of	  EBUS	  
The	   limitations	   of	   EBUS	   are:	   difficult	   airway	   examination,	   due	   to	  
anatomic	   anomalies,	   false-­‐negative	   results	   of	   biopsies,	   inability	   to	  
reach	   certain	   lymph	  nodes	   stations	   (station	   5	   and	  6),	   and	   time	   and	  
training	  required	  to	  obtain	  optimal	  samples.16	  	  
Contraindications	  are	  similar	  to	  those	  of	  usual	  flexible	  bronchoscopy.	  
Absolute	   contraindications	   are	   severe	   arrhythmia,	   heart	   failure,	  
severe	  hypoxia.	  Other	  contraindications	  related	  to	  increased	  bleeding	  
risk	   in	   patients	   with	   antiplatelet	   or	   anticoagulation	   treatment,	  
thrombocytopenia	  and	  elevated	  blood	  levels	  of	  urea	  and	  creatinine.17	  
EBUS-­‐TBNA	  is	  usually	  a	  safe	  procedure;	  complications	  being	  rare.	  
This	   complications	   consist	   of	   pneumomediastinum,	   pneumothorax	  
and	  hemomediastinum.	  
Usually,	  at	  the	  end	  of	  the	  procedure,	  chest	  X-­‐ray	  exame	  is	  perfomed,	  
but	  it	  is	  not	  mandatory.	  Because	  of	  the	  real-­‐time	  ultrasound	  imaging,	  
major	   vessel	   puncture	   is	   theoretically	   less	   likely	   compared	   with	  
conventional	  transbronchial	  needle	  aspiration	  (cTBNA).	  Major	  vessel	  
puncture	   (aorta)	   has	   been	   described	   during	   cTBNA.	   Although	  
unintended	  puncture	  of	  major	  vessels	  can	  lead	  to	  hematoma,	  this	   is	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usually	  clinically	  non	  relevant.18,19	   Infectious	  complications	  have	  also	  
been	  rarely	  reported.20	  
	  
EBUS-­‐TBNA	  specimen	  preparation	  techniques	  
Adequate	   preparation	   of	   specimens	   for	   cytology	   is	   essential	   for	  
ensuring	  that	  EBUS-­‐TBNA	  has	  good	  diagnostic	  yield.	  Procurement	  of	  
adequate	   specimens	   is	   key	   to	   provide	   a	   specific	   histologic	   and	  
molecular	  diagnosis	  of	  lung	  cancer.	  
In	   the	   literature	   several	   techniques	   for	   specimen	   acquisition	   and	  
preparation	   have	   been	   described,	   but	   no	   comparison	   of	   these	  
multiple	  techniques	  has	  been	  performed.	  Usually,	  cytology	  slides	  are	  
adequate	   for	   the	   diagnosis	   of	   lung	   cancer	   and	   its	   subclassification,	  
but	   the	  material	   is	   genarally	   inadequate	   for	  molecular	   testing.	   Cell	  
block	  formation	  usually	  improve	  the	  ability	  to	  determine	  lung	  cancer	  
subclassification	  and	  allows	  molecular	  testing.	  
Cytology	  slides	  were	  prepared	  as	  follows:	  the	  sample	  is	  placed	  on	  the	  
cytology	  slide,	  another	  slide	  or	  a	  coverslip	   is	  placed	  against	   the	   first	  
slide	   at	   an	   angle	   of	   45°	   or	   is	   placed	  horizontally	   on	   top	  of	   it	   and	   is	  
gently	   slid	   along	   the	   base	   slide	   until	   it	   reaches	   the	   opposite	   end,	  
causing	  the	   liquid	  sample	  to	  spread	  uniformly.	  The	  sample	  can	  than	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be	   fixed	  with	   95%	   ethanol.	   The	   slide	   can	   be	   stained	   1	  minute	  with	  
heamatoxylin	   for	   rapid	   on-­‐site	   evaluation	   (ROSE)	   by	   a	  
cytopathologist;	   later	   the	   Papanicolau	   staining	   with	   orange	   A	   and	  
eosin	  can	  be	  completed	  in	  the	  laboratory.21	  	  
Cell	  block	  was	  obtained	  placing	  the	  sample	  into	  formaline.	  Sample	  is	  
then	   centrifuged,	   concentrating	   the	   cellular	   material	   that	   was	   in	  
suspension.	   The	   fragments	   as	   well	   as	   the	   resulting	   sediment	   are	  
embedded	   in	   paraffin	   as	   a	   tissue,	   making	   it	   is	   possible	   to	   obtain	  
histological	   sections	   that	   will	   be	   examined	   using	   histochemistry	   or	  
immunohistochemistry.21	  	  






The	   optimal	   method	   for	   EBUS-­‐TBNA	   specimen	   preparation	   is	  
controversial.	  Specimen	  acquisition	  and	  preparation	  are	  key	  to	  obtain	  
adequate	  tissue	  for	  diagnosis,	  accurate	  and	  complete	  staging	  of	  lung	  
cancer	   with	   EBUS	   TBNA.	   Thus,	   conventional	   cytology	   staining	   does	  
not	  always	  provide	  sufficient	  information	  and	  more	  material	  is	  often	  
required	  to	  plan	  adequate	  treatment.	  
Multiple	   techniques	   for	   specimen	   acquisition	   and	   preparation	   have	  
been	   reported	   in	   the	   literature	   though	   no	   direct	   comparisons	   of	  
these	   techniques	   have	   been	   performed	   until	   now	   within	   the	   same	  
institution.	   Rather,	   the	   results	   of	   different	   techniques	   used	   by	  
different	  authors	  were	  compared22;	  thus	  different	  levels	  of	  expertise	  
across	  centers	  may	  have	  influenced	  the	  comparison.	  
In	   this	   study	   we	   compared	   multiple	   techniques	   for	   EBUS-­‐TBNA	  
specimen	  acquisition	  and	  processing	  in	  a	  single-­‐institution	  experience.	  
We	   compared	   five	   specimen-­‐processing	   techniques	   that	   we	   used	  
over	  the	  study	  period	  2012-­‐2014:	  1)	  cytology	  slides;	  2)	  cell-­‐block;	  3)	  
core-­‐tissue;	  4)	  cytology	  +	  cellblock;	  5)	  cytology	  +	  core	  tissue.	  
This	  study	  was	  approved	  by	  the	  our	  institutional	  review	  board.	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We	   have	   retrospectively	   reviewed	   the	   data	   of	   199	   consecutive	  
patients	   (71%	   male;	   mean	   age	   61±15	   SD	   years)	   undergoing	   EBUS-­‐
TBNA	  of	  mediastinal-­‐hilar	  lymphadenopathy	  (lymph	  node	  mean	  size,	  
27+13	   SD	   mm)	   for	   suspect	   lung	   cancer	   metastasis	   (n=139)	   or	  
granulomatosis	   (n=60)	   at	   the	   Center	   for	   Thoracic	   Surgery,	   Insubria	  
University-­‐Varese,	  in	  2012-­‐2014.	  	  
All	  procedures	  were	  performed	  by	  two	  experienced	  bronchoscopists	  
on	  rotation,	  using	  21-­‐G	  or	  22-­‐G	  needle,	  3	  passes,	  aspiration,	  without	  
rapid	   on-­‐site	   evaluation	   (ROSE).	   Specimens	  were	   read	   by	   the	   same	  
expert	  thoracic	  pathologists.	  
	  
EBUS-­‐TBNA	  procedures	  
Under	  a	  moderate	  sedation	  by	  intravenous	  fentanyl,	  midazolam	  and	  
lidocaine	   topical	   anesthesia,	   standard	  bronchoscopy	  was	  performed	  
for	  initial	  inspection	  and	  visualization	  of	  the	  airways	  (Olympus	  BF180	  
serie	   videobronchoscope).	   After	   this	   first	   evaluation	   the	   ultrasound	  
examination	   (EBUS	   broncoscope	   Olympus	   convex	   probe	   7.5	   MHz)	  
was	   introduced	   into	   the	   airway	   and	   ultrasound	   scanning	   of	   the	  
mediastinum	   and	   hilum	   was	   performed	   to	   identify	   visible	   lymph	  
nodes.	   After	   lymph	   node	   identification	   under	   realtime	   ultrasound	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guide,	  the	  samples	  were	  taken	  with	  22	  or	  21	  gauge	  needle.	  The	  stylet	  
inserted	   into	   the	   needle	   was	   used	   to	   clean	   bronchial	   or	   cartilage	  
fragments	  and	  then	  	  negative	  suction	  was	  connected	  by	  vacuum-­‐lock	  
syringe.	  
At	   least	   3	   specimens	   were	   obtained	   for	   each	   lymph	   node	   with	   15	  
excursions	  each	  time.	  	  
The	   collected	  material	   was	   prepared	  with	   different	  modalities	   over	  
the	  study	  period.	  
Cytology	  slide	  
In	  first	  time	  we	  prepared	  always	  a	  cytological	  slide	  crawled	  two	  slides	  
and	  using	  both	  air-­‐dried	  and	  wet-­‐fixed	  methods	  and	  then	  was	  stained	  
using	  Papanicolau	  test.	  	  
Cell-­‐block	  
To	  prepared	  cell-­‐block	   the	   sampled	  material	  was	  pushed	  out	  of	   the	  
needle	  with	   the	  wire	  stylet	  directly	   into	  an	   integrity	  cellular	  storage	  
solution	   to	   obtain	   a	   tissue	   coagulum	   clot	   and	   then	   the	   sample	  was	  
processed	  to	  get	  4-­‐5	  micron	  section	  on	  glass	  slide.	  The	  sections	  were	  






The	   sampled	   core-­‐tissue	   was	   prepared	   pushed	   out	   directly	   in	  
formaline	  solution	  and	  treated	  as	  a	  histological	  issue.	  
Cytological	   slides	  were	   read	   in	   combination	  with	   cell-­‐block	   or	   core-­‐
tissue	  for	  each	  sample,	  to	  assess	  the	  impact	  of	  dual-­‐modality	  reading.	  
To	  assess	  the	  processing-­‐technique	  diagnostic	  accuracy	  in	  cases	  with	  
cancer-­‐negative	   EBUS-­‐TBNA	   finding,	   we	   used	   as	   diagnostic	   gold	  
standard	   respectively	   the	   surgical	   N	   status	   in	   operated	   lung	   cancer	  
patients,	  or	  1-­‐year	  follow-­‐up.	  
We	  evaluated	  the	  diagnostic	  yield,	  accuracy	  and	  area	  under	  the	  curve	  





In	   the	   majority	   of	   cases,	   EBUS-­‐TBNA	   was	   performed	   to	   obtain	   the	  
diagnosis	   of	   lymph	  node	  under	   examination;	   only	   in	   3	  patients	  was	  
EBUS-­‐TBNA	  made	  for	  lung	  cancer	  staging.	  	  
The	   sampled	   	   lymph	   node	   stations	   were:	   #7	   in	   60%	   of	   patients;	  
#4R/4L	  in	  32%;	  #10R/11R/10L/11L	  in	  7%;	  #2R/2L	  in	  1%.	  	  
Mean	  duration	  of	  the	  procedure	  was	  24	  +	  9	  minutes.	  No	  complication	  
occured.	  
Five	   different	   specimen-­‐processing	   techniques	   were	   evaluated	   and	  
compared	  over	  the	  study	  period,	  in	  sequential	  order:	  cytology	  slides	  
(n=42	  patients);	  cell-­‐block	  (n=25);	  core-­‐tissue	  (n=60);	  combination	  of	  
cytology	   slides+core-­‐tissue	   (n=51);	   combination	   of	   cytology	  
slides+cell-­‐block	  (n=21).	  	  
Diagnostic	   yield,	   accuracy	   and	   area	   under	   the	   curve	   (AUC)	  were	   as	  
follows.	  Cytology	  slides:	  81%,	  80%,	  0.90;	   cell-­‐block:	  48%,	  33%,	  0.67;	  
core-­‐tissue:	  87%,	  99%,	  0.96;	  cytology	  slides+core-­‐tissue:	  81%,	  100%,	  
1.00;	   cytology	   slides+cell-­‐block:	   86%,100%,	   1.00	   (Figure	   6	   and	   7).	  
Cytology	   slides	   and	   core-­‐tissue	   methods	   showed	   not	   significantly	  
different	  diagnostic	  yield	  (p=0.435)	  and	  	  AUC	  (p=0.152).	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We	  also	  evaluated	  the	  indipendent	  predictors	  of	  diagnostic	  accurancy	  
by	   multivariate	   analysis,	   shown	   Table	   1.	   The	   only	   independent	  
predictor	   of	   diagnostic	   accuracy	   for	   malignancy	   was	   the	   sample	  
processing	  technique	  (p<0.01).	  
	  
 





Figure	  7	  AUC	  of	  combination	  of	  cytology	  with	  cell	  block	  and	  core	  biopsy	  
	  
Table	  1	  Predictors	  of	  diagnostic	  accurancy	  of	  EBUS-­‐TBNA	  
	   UNIVARIATE	   MULTIVARIATE	  
	   OR	   95%	  CI	   p	   OR	   95%	  CI	   p	  
Progressive	  number	  of	  cases	  	  
(1-­‐50	  v	  51-­‐100	  v	  101-­‐150	  v	  151-­‐199)	  
1.14	   0.75-­‐1.74	   0.52	   1.25	   0.74-­‐2.11	   0.41	  
LN	  diameter	  (>	  10	  mm)	   1.01	   0.98-­‐1.04	   0.49	   1.01	   0.98-­‐1.04	   0.37	  
Needle	  (21G	  v	  22G)	   1.52	   0.66-­‐3.50	   0.32	   1.83	   0.72-­‐4.62	   0.21	  
Thoracic	  surgeon	  v	  Pulmonologist	   1.28	   0.64-­‐2.54	   0.48	   1.26	   0.59-­‐2.66	   0.55	  
Specimen	  preparation	   0.62	   0.44-­‐0.87	   0.01	   0.54	   0.37-­‐0.78	   <0.01	  
Disease	  (malignant	  v	  benign)	   1.29	   0.64-­‐2.61	   0.47	   1.26	   0.74-­‐2.11	   0.59	  
From:	  Rotolo	  N	  et	  al.	  Factors	  affecting	  accuracy	  of	  EBUS-­‐TBNA	  during	  the	   learning	  curve.	  To	  be	  
presented	   to	   19th	   World	   Congress	   for	   bronchology	   and	   interventional	   pulmonology,	   Florence,	  





EBUS-­‐TBNA	  has	  become	  the	  first-­‐line	  tool	  for	  staging	  and	  diagnosis	  of	  
patients	  with	   suspected/diagnosed	   lung	  cancer.	  Adequate	  specimen	  
acquisition	   during	   EBUS-­‐TBNA	   is	   very	   important	   to	   achieve	   a	  
definitive	   diagnosis	   and,	   in	   patients	   already	   diagnosed,	   to	   perform	  
mediastinal	  staging	  of	  lung	  cancer.	  	  
In	   high	   volume	   centers,	   ROSE	   is	   used	   in	   daily	   clinical	   practice.	   This	  
technique	   offers	   an	   immediate	   and	   accurate	   feedback	   on	   the	  
diagnosis	   and	   quality	   of	   specimen,	   and	   the	   number	   of	   needle	  
aspirations	   may	   be	   reduced;	   however	   there	   are	   no	   randomized	  
studies	  supporting	  the	  use	  of	  ROSE.	  	  
Molecular	   analysis	   can	   be	   routinely	   performed	   on	   the	   majority	   of	  
cytological	   samples	   obtained	   by	   EBUS-­‐guided	   and	   conventional	  
TBNA9,10.	   However,	   the	   outcome	   of	   molecular	   analysis	   largely	  
depends	  on	  the	  absolute	  number	  of	  vital	   tumor	  cells,	  percentage	  of	  
tumor	   cells	   present	   in	   the	   material	   and	   the	   sensitivity	   of	   the	  
molecular	   test	   that	   is	   being	   utilized;	   both	   smear	   and	   cell	   block	  
preparations	  or	  core	  tissue	  can	  be	  utilized	  for	  molecular	  testing.9,10	  
Van	  der	  Heijden	  et	  al	  in	  2014	  published	  guidelines	  for	  acquisition	  and	  
preparation	  of	  transbronchial	  needle	  aspiration	  specimens	  to	  be	  used	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for	  the	  diagnosis	  and	  molecular	  testing	  of	  patients	  with	  lung	  cancer.22	  
They	   presented	   an	   evidence-­‐based	   guideline	   to	   optimize	   the	   tissue	  
sampling	   procedure	   outcome	   in	   daily	   clinical	   practice.	   There	   is	  
enough	   evidence	   that	   3	   needle	   aspirations	   during	   EBUS-­‐TBNA	  
provide	  maximum	  yield;	   the	  needle	   size	   (whether	  21	  or	  22	  G)	  does	  
not	   influence	  the	  diagnostic	  yield.	  Van	  der	  Heijden	  et	  al22,	   reviewed	  
the	   pertinent	   literature,	   to	   evaluate	   if	   specimen	   preparation	  
techniques	  can	  affect	  the	  quantity	  of	  biologic	  material	  retrieved	  and	  
accurancy	   of	   specimen	   diagnosis.	   There	   are	   no	   pubblished	   trials	  
comparing	   cell-­‐block	   and	   core-­‐tissue	   techniques;	   both	   were	   found	  
valuable	   for	   diagnosis.	   	   According	   to	   Van	   der	   Heijden	   et	   al22	   there	  
does	  not	  appear	  to	  be	  a	  superior	  method	  for	  specimen	  preparation,	  
the	  optimal	  specimen	  preparation	  depending	  on	  the	  preference	  and	  
expertise	   of	   the	   local	   pathologist.	   However	   these	   conclusions	  were	  
based	   on	   comparison	   of	   specimen	   acquisition	   methods	   between	  
different	  centers,	  and	  different	  levels	  of	  expertise	  across	  centers	  may	  
have	  influenced	  the	  comparison.	  	  
A	  spanish	  study21	  evaluated	  the	  contribution	  of	  EBUS-­‐TBNA	  with	  cell	  
block	  analysis	  to	  the	  diagnostic	  yield	  in	  lung	  cancer;	  in	  this	  study	  cell-­‐
block	   improved	   the	  pathologic	  diagnosis	   attained	  with	   conventional	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smears	  (7.7%).	  Cell	  block	  obtained	  during	  EBUS-­‐TBNA	  allowed	  	  EGFR	  
mutation	   analysis	   in	   60%	   of	   cases	   and	   other	   clinically	   relevant	  
information	  in	  30%	  of	  those	  participating	  in	  the	  study.21	  	  
In	   the	   present	   study,	   in	   order	   to	   avoid	   confounding	   from	   across-­‐
centers	   comparison,	   for	   the	   first	   time	   we	   compared	   multiple	  
techniques	   of	   EBUS-­‐TBNA	   specimen	   acquisition	   and	   processing	  
performed	   in	   a	   single-­‐institution	   experience	   (Ospedale	   di	   Circolo	   di	  
Varese,	  Center	  for	  Thoracic	  Surgery	  and	  division	  of	  Pneumology).	  	  
The	  main	   result	   of	   our	   study	   is	   that	   cytology	   slides	   and	   core-­‐tissue	  
preparations	   had	   high	   and	   similar	   diagnostic	   performance	   (Figure	   6	  
and	  7).	  Combination	  of	  cytology	  slides	  with	  core-­‐tissue,	  or	  with	  cell-­‐
block,	   showed	   the	  highest	   performance;	   however	   it	   is	   important	   to	  







In	   conclusion,	   after	   comparing	   different	   EBUS-­‐TBNA	   specimen	  
acquisition	   technique	   in	   a	   single	   center,	   and	   after	   considering	   the	  
ongoing	  discussion	  in	  the	  pertinent	   literature	  we	  think	  that	  the	  best	  
technique	   to	   obtain	   the	   tissue	   specimen	   for	   a	   definitive	   diagnosis	  
depends	  on	  the	  preference	  and	  expertise	  of	   the	  pathologist	   in	  each	  
center.	   A	   multidisciplinary	   effort	   and	   collaboration	   between	   EBUS	  
bronchoscopists	   and	   cytopathologists	   is	   required	   to	   achieve	   the	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